In the latest close session, Medpace (MEDP) was up +1.55% at $326.03. The stock outpaced the S&P 500's daily gain of 0.48%. Meanwhile, the Dow experienced a drop of 0.02%, and the technology-dominated Nasdaq saw an increase of 0.94%.
Heading into today, shares of the provider of outsourced clinical development services had gained 4.9% over the past month, outpacing the Medical sector's gain of 2.8% and lagging the S&P 500's gain of 5.13%.
Invest in Gold
Investors will be eagerly watching for the performance of Medpace in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 21, 2025. On that day, Medpace is projected to report earnings of $2.99 per share, which would represent year-over-year growth of 8.73%. Meanwhile, our latest consensus estimate is calling for revenue of $539.75 million, up 2.21% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $12.71 per share and revenue of $2.18 billion, indicating changes of +0.63% and +3.54%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Medpace. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, Medpace holds a Zacks Rank of #3 (Hold).
In the context of valuation, Medpace is at present trading with a Forward P/E ratio of 25.26. Its industry sports an average Forward P/E of 16.21, so one might conclude that Medpace is trading at a premium comparatively.
We can additionally observe that MEDP currently boasts a PEG ratio of 5.79. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical Services industry stood at 1.47 at the close of the market yesterday.
